Medicine and Health Sciences Commons^™

Histone Deacetylase Inhibitors And Mithramycin A Impact A Similar Neuroprotective Pathway At A Crossroad Between Cancer And Neurodegeneration, Sama F. Sleiman, Jill Berlin, Manuela Basso, Saravanan S. Karuppagounder, Jürgen Rohr, Rajiv R. Ratan

Pharmaceutical Sciences Faculty Publications

Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target sites (GC box). HDACi, on the other hand, modulate the activity of class I and II histone deacetylases. They mediate their protective function, in part, by regulating the acetylation status of histones or transcription factors, including Sp1, and in turn chromatin accessibility to the transcriptional machinery. Because these two classes of structurally and functionally diverse compounds mediate similar therapeutic …